pargyline has been researched along with rasagiline in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (10.53) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (73.68) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Toprakçí, M; Yelekçi, K | 1 |
| Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R | 1 |
| Cheng, M; Guo, J; Jiang, N; Li, Q; Liang, N; Liu, J; Nong, X; Pang, C; Qin, Y; Tang, C; Tang, W; Xie, SS; Zhang, Z | 1 |
| Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M | 1 |
| Finberg, JP; Youdim, MB | 1 |
| Duvoisin, RC; Finberg, JP; Heikkila, RE; Youdim, MB | 1 |
| Carrillo, MC; Kitani, K; Maruyama, W; Naoi, M; Yamamoto, T; Youdim, M | 1 |
| Maruyama, W; Naoi, M; Youdim, MB | 1 |
| Amit, T; Bar-Am, O; Yogev-Falach, M; Youdim, MB | 1 |
| Lazarovici, P; Lecht, S; Tabakman, R | 1 |
| Jenner, P | 1 |
| Fridkin, M; Youdim, MB; Zheng, H | 1 |
| Amit, T; Bar-Am, O; Weinreb, O; Youdim, MB | 1 |
| Amit, T; Bar-Am, O; Chillag-Talmor, O; Weinreb, O; Youdim, MB | 1 |
| Olanow, CW | 1 |
| Amit, T; Bar-Am, O; Mandel, S; Sagi, Y; Weinreb, O; Youdim, MB | 1 |
| Akao, Y; Maruyama, W; Naoi, M; Shamoto-Nagai, M; Yamaoka, Y; Yi, H | 1 |
| Miklya, I | 1 |
| Amit, T; Bar-Am, O; Berdichevski, A; Binah, O; Kleiner, Y; Liani, E; Maor, G; Reiter, I; Youdim, MB | 1 |
3 review(s) available for pargyline and rasagiline
| Article | Year |
|---|---|
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Topics: Amphetamines; Animals; Antiparkinson Agents; Apoptosis; Clinical Trials as Topic; Drug Evaluation, Preclinical; Haplorhini; Humans; Inactivation, Metabolic; Indans; Mice; Mice, Transgenic; Models, Neurological; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Oxepins; Oxidative Stress; Pargyline; Parkinson Disease; Propylamines; Selegiline | 2004 |
Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway.
Topics: Animals; Cell Death; Humans; Indans; Nerve Growth Factors; Neuroprotective Agents; Pargyline; Propylamines; Protein Kinase C; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2005 |
Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety.
Topics: Amyloid beta-Protein Precursor; Animals; Humans; Indans; Neuroprotective Agents; Pargyline; Propylamines; Signal Transduction; Structure-Activity Relationship | 2006 |
16 other study(ies) available for pargyline and rasagiline
| Article | Year |
|---|---|
Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.
Topics: Crystallography, X-Ray; Kinetics; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2005 |
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics | 2015 |
Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Line, Tumor; Cell Survival; Clorgyline; Dose-Response Relationship, Drug; Drug Design; Humans; Indans; Male; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship | 2020 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
MAO type B inhibitors as adjunct to L-dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Alkynes; Animals; Brain; Drug Therapy, Combination; Humans; Indans; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Parkinson Disease; Parkinson Disease, Secondary; Pyridines; Receptors, Dopamine; Selegiline; Structure-Activity Relationship; Tyramine | 1987 |
Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzylamines; Brain; Dopamine; Indans; Indenes; Male; Mice; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Oxidation-Reduction; Pargyline; Pyridines; Selegiline; Tryptamines | 1985 |
Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.
Topics: Animals; Apoptosis; Humans; Indans; Molecular Structure; Molsidomine; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Pargyline; Propylamines; Rats; Rats, Inbred F344; Selegiline; Tumor Cells, Cultured | 2000 |
Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.
Topics: Adrenergic Agents; Apoptosis; Cell Line; Humans; Indans; Molsidomine; Neuroprotective Agents; Nitric Oxide Donors; Oxidopamine; Pargyline; Propylamines; Stereoisomerism | 2001 |
The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antiparkinson Agents; Cell Line, Tumor; Indans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Models, Biological; Neuroprotective Agents; Pargyline; PC12 Cells; Peptide Fragments; Propylamines; Protein Processing, Post-Translational; Rats; Structure-Activity Relationship | 2003 |
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?
Topics: Animals; Apoptosis; Enzyme Inhibitors; Humans; Indans; Models, Chemical; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Neurotoxins; Pargyline; Parkinson Disease; Propylamines; Time Factors | 2004 |
Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Topics: Animals; Brain; Drug Delivery Systems; In Vitro Techniques; Indans; Iron Chelating Agents; Male; Mitochondria; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurodegenerative Diseases; Neuroprotective Agents; Pargyline; Parkinson Disease; Piperazines; Propylamines; Quinolines; Rats; Rats, Sprague-Dawley | 2004 |
Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine.
Topics: Amyloid beta-Protein Precursor; Apoptosis; Apoptosis Regulatory Proteins; Base Sequence; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Brain-Derived Neurotrophic Factor; Caspase 3; Caspases; Cell Line, Tumor; Cell Survival; DNA Primers; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; Humans; Immunoblotting; Indans; Isoelectric Point; Membrane Proteins; Models, Biological; Molecular Sequence Data; Nerve Growth Factors; Neurons; Pargyline; Poly(ADP-ribose) Polymerases; Propylamines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2005 |
Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Humans; Indans; Neuroprotective Agents; Pargyline; Parkinson Disease; Practice Guidelines as Topic; Practice Patterns, Physicians'; Propylamines; Selegiline; Treatment Outcome | 2006 |
Neuroprotection by propargylamines in Parkinson's disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers.
Topics: Alkynes; Cell Death; Cell Line, Tumor; Energy Metabolism; Genetic Markers; Glial Cell Line-Derived Neurotrophic Factor; Humans; Indans; Membrane Potentials; Mitochondria; Neuroblastoma; Neuroprotective Agents; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pargyline; Parkinson Disease; Propylamines; Proto-Oncogene Proteins c-bcl-2; Selegiline | 2007 |
[A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Topics: Adrenergic Uptake Inhibitors; Animals; Brain Stem; Catecholamines; Clorgyline; Indans; Learning; Monoamine Oxidase Inhibitors; Neurons; Neuroprotective Agents; Pargyline; Rats; Selegiline; Tetrabenazine | 2008 |
TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity.
Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cardiotonic Agents; Caspase 3; Cell Line, Tumor; Cells, Cultured; Doxorubicin; Female; Heart Diseases; Heart Ventricles; Humans; Indans; Myocytes, Cardiac; Pargyline; Propylamines; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Stereoisomerism | 2008 |